Drug
Isis 301012
Isis 301012: highest development phase Phase 2, developed by United Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ISIS 301012 NCT00280995 | Phase 2 | Hypercholesterolemia, Familial |
Latest
No recent events.
Follow Isis 301012 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.